🔗 Share this article

As the US proceeds with historic adjustments to its vaccination schedules, an unexpected name has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on coronavirus vaccinations throughout the global health crisis and has focused upon potential deaths following COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Schedule

Health officials planned to reveal sweeping changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would put the US out of alignment with a large portion of the world with no evidence for improved outcomes. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to run the office this year.

Consolidating Power at the Regulatory Body

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric shot schedules in the US so as to align more like Denmark's approach, a society with nationalized medicine and a population about the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccination policy – usually the domain of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious experience in medication creation, oversight or management, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Past commissioners of CBER would “grasp laws and regulations and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who ran the center have had.”

The drug center has an vast workload at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes thousands of generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those have to be looked after,” Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a major leadership aspect to the position, which oversees more than 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” Woodcock added.

Agency Reaction and Disputed Initiatives

In response to questions about Dr. Høeg's qualifications and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a representative said that the “inquiries are based on incorrect presumptions”.

“Her experience matches the duties of her job,” the official explained, pointing to the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s new expedited review system, a controversial rapid drug-approval program that reportedly worried her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who takes the choices?” Howard said. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards less stringent oversight of all drugs, with the exception of vaccines.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if concerning, track record, Howard said. She authored a analysis using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current administration included changing guidelines for recently developed shots and discontinuing “unnecessary” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and works backwards to accommodate the science in a very disingenuous, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|